Advertisement
Screener

ACHILLION PHARMACEUTICALS INC Patents: Applications Rejected

ACHILLION PHARMACEUTICALS INC Patent Applications Rejected

24 applications abandoned without a patent; the status gives the reason, newest filing first, as the USPTO Open Data Portal records them; the company is the first-named applicant. The application number opens the full record at Patent Center.

  • 2022-09-02: Application 17909228; Invention OCULAR DRUG DEPOT FOR COMPLEMENT-MEDIATED DISORDERS; Applicant Achillion Pharmaceuticals, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2022-08-16: Application 17800013; Invention HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERS; Applicant Achillion Pharmaceuticals, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2021-12-29: Application 17564446; Invention QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERS; Applicant Achillion Pharmaceuticals, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
  • 2021-02-09: Application 17267362; Invention PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERS; Applicant Achillion Pharmaceuticals, Inc.; Status Abandoned -- Failure to Respond to an Office Action.
FiledApplicationInventionApplicantStatusPublished asInventor nameInventor countryExaminer
2022-09-0217909228OCULAR DRUG DEPOT FOR COMPLEMENT-MEDIATED DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20230126447A1
Mingjun Huang
Steven Zelenkofske
David Boyer
Jose Rivera
Jason Allan Wiles
United States
United States
United States
United States
United States
NOLAN, JASON MICHAEL
2022-08-1617800013HETEROARYL COMPOUNDS FOR TREATMENT OF COMPLEMENT FACTOR D MEDIATED DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20250197403A1
Jason Allan Wiles
Venkat Rao Gadhachanda
United States
United States
RZECZYCKI, PHILLIP MATTHEW
2021-12-2917564446QUINAZOLINE AND INDOLE COMPOUNDS TO TREAT MEDICAL DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20220119400A1
Jason Allan WILES
Avinash PHADKE
United States
United States
WARD, PAUL V
2021-02-0917267362PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT FACTOR D MEDICAL DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20230022157A1
Jason Allan Wiles
Venkat Rao Gadhachanda
Kyle J. Eastman
Godwin Pais
United States
United States
United States
United States
RAO, PADMAJA S
2020-11-2417058547COMPLEMENT ALTERNATIVE PATHWAY-ASSOCIATED NEPHROPATHY BIOMARKERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20210215714A1
Mingjun HUANG
Steven D. PODOS
Wengang YANG
Yongsen ZHAO
United States
United States
United States
United States
YAKOVLEVA, GALINA M
2020-09-0917015171ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF MEDICAL DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20210269458A1
Jason Allan WILES
Avinash S. PHADKE
Milind DESHPANDE
Atul AGARWAL
Dawei CHEN
Venkat Rao GADHACHANDA
Akihiro HASHIMOTO
Godwin PAIS
Qiuping WANG
Xiangzhu WANG
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
YOO, SUN JAE
2018-08-0216053716THERAPEUTIC REGIMENS FOR TREATMENT OF PAROXYSMAL NOCTURNAL HEMOGLOBINURIAAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20190038623A1
Mingjun Huang
Dharaben Patel
Steven D. Podos
United States
United States
United States
KOSTURKO, GEORGE W
2018-06-2916024021SUBSITUTED ALIPHANES, CYCLOPHANES, HETERAPHANES, HETEROPHANES, HETERO-HETERAPHANES AND METALLOCENES USEFUL FOR TREATING HCV INFECTIONSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180303800A1
Jason Allan Wiles
Qiuping Wang
Akihiro Hashimoto
Godwin Pais
Xiangzhu Wang
Venkat Gadhachanda
Avinash Phadke
Milind Deshpande
Dawei Chen
United States
United States
United States
United States
United States
United States
United States
United States
United States
CHEN, PO-CHIH
2018-06-1216006533ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180291047A1
Jason Allan Wiles
Godwin Pais
Akihiro Hashimoto
Venkat Rao Gadhachanda
Qiuping Wang
Dawei Chen
Xiangzhu Wang
Atul Agarwal
Milind Deshpande
Avinash S. Phadke
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
BARKER, MICHAEL P
2018-06-1216006520ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180291046A1
Jason Allan Wiles
Godwin Pais
Akihiro Hashimoto
Venkat Rao Gadhachanda
Qiuping Wang
Dawei Chen
Xiangzhu Wang
Atul Agarwal
Milind Deshpande
Avinash S. Phadke
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
BARKER, MICHAEL P
2018-06-1216006476Alkyne Compounds for Treatment of Complement Mediated DisordersAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180298043A1
Jason Allan Wiles
Godwin Pais
Akihiro Hashimoto
Venkat Rao Gadhachanda
Qiuping Wang
Dawei Chen
Xiangzhu Wang
Atul Agarwal
Milind Deshpande
Avinash S. Phadke
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
BARKER, MICHAEL P
2017-11-2015818559ALKYNE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20180072762A1
Jason Allan Wiles
Godwin Pais
Akihiro Hashimoto
Venkat Rao Gadhachanda
Qiuping Wang
Dawei Chen
Xiangzhu Wang
Atul Agarwal
Milind Deshpande
Avinash S. Phadke
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
BARKER, MICHAEL P
2017-07-2515659464COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTIONACHILLION PHARMACEUTICALS, INC.
JANSSEN PHARMACEUTICALS, INC.
Abandoned -- Failure to Respond to an Office ActionUS20170319572A1
Maria Gloria Beumont
Lieve Bijnens
Lawrence M. Blatt
Sushmita Mukherjee Chanda
John Fry
Eugene Jans
Thomas Naoki Kakuda
Sivi Mahadevan
Roel Mertens
Gaston Rafael Picchio
Alex Van Dijck
Peter Van Remoortere
David Apelian
Dawei Chen
Milind Deshphande
James Hui
Avinash Phadke
France
Belgium
United States
United States
United States
Belgium
United States
Belgium
Belgium
United States
Belgium
United States
United States
United States
United States
United States
United States
CRANE, LAWRENCE E
2017-07-2115656872COMBINATION DRUG TREATMENT FOR HEPATITIS C INFECTIONACHILLION PHARMACEUTICALS, INC.
JANSSEN PHARMACEUTICALS, INC.
Abandoned -- Failure to Respond to an Office ActionUS20180021361A1
Maria Gloria Beumont
Lieve Bijnens
Lawrence M. Blatt
Sushmita Mukherjee Chanda
John Fry
Eugene Jans
Thomas Naoki Kakuda
Sivi Mahadevan
Roel Mertens
Gaston Rafael Picchio
Alex Van Dijck
Peter Van Remoortere
David Apelian
Dawei Chen
Milind Deshphande
James Hui
Avinash Phadke
France
Belgium
United States
United States
United States
Belgium
United States
Belgium
Belgium
United States
Belgium
United States
United States
United States
United States
United States
United States
BAKSHI, PANCHAM
2017-07-2115656821Combination Therapy Regimen For Treatment Of Selected HCV GenotypesACHILLION PHARMACEUTICALS, INC.
JANSSEN PHARMACEUTICALS, INC.
Abandoned -- Failure to Respond to an Office ActionUS20180021360A1
Maria Gloria Beumont
Lieve Bijnens
Lawrence M. Blatt
Sushmita Mukherjee Chanda
John Fry
Eugene Jans
Thomas Naoki Kakuda
Sivi Mahadevan
Roel Mertens
Gaston Rafael Picchio
Alex Van Dijck
Peter Van Remoortere
David Apelian
Dawei Chen
Milind Deshphande
James Hui
Avinash Phadke
France
Belgium
United States
United States
United States
Belgium
United States
Belgium
Belgium
United States
Belgium
United States
United States
United States
United States
United States
United States
BAKSHI, PANCHAM
2017-04-2415494926Factor D Inhibitors Useful for Treating Inflammatory DisordersAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20170226142A1
Jason Allan Wiles
Milind Deshpande
United States
United States
JACKSON, SHAWQUIA
2016-08-2415246049COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160361329A1
Jason Allan Wiles
Avinash S. Phadke
Milind Deshpande
Atul Agarwal
Dawei Chen
Venkat Rao Gadhachanda
Akihiro Hashimoto
Godwin Pais
Qiuping Wang
Xiangzhu Wang
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
SHTERENGARTS, SAMANTHA L
2016-08-2415245945PHOSPHONATE COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160362432A1
Jason Allan Wiles
Avinash S. Phadke
Milind Deshpande
Atul Agarwal
Dawei Chen
Venkat Rao Gadhachanda
Akihiro Hashimoto
Godwin Pais
Qiuping Wang
Xiangzhu Wang
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
FINN, MEGHAN R
2016-08-2415245872ETHER COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160362433A1
Jason Allan Wiles
Avinash S. Phadke
Milind Deshpande
Atul Agarwal
Dawei Chen
Venkat Rao Gadhachanda
Akihiro Hashimoto
Godwin Pais
Qiuping Wang
Xiangzhu Wang
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
DRAPER, LESLIE A ROYDS
2016-08-2415245788ARYL, HETEROARYL, AND HETEROCYCLIC COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERSAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160362399A1
Jason Allan Wiles
Avinash S. Phadke
Milind Deshpande
Atul Agarwal
Dawei Chen
Venkat Rao Gadhachanda
Akihiro Hashimoto
Godwin Pais
Qiuping Wang
Xiangzhu Wang
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
FINN, MEGHAN R
2015-07-2114805421STABILIZED NUCLEOTIDES FOR MEDICAL TREATMENTAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20160016986A1
Milind Deshpande
Jason Allan Wiles
Akihiro Hashimoto
Avinash Phadke
United States
United States
United States
United States
CRANE, LAWRENCE E
2014-04-1414252494DEUTERATED NUCLEOSIDE PRODRUGS USEFUL FOR TREATING HCVAchillion Pharmaceuticals, Inc.Abandoned -- Failure to Respond to an Office ActionUS20140309164A1
Milind Deshpande
Jason Allan Wiles
Akihiro Hashimoto
Avinash Phadke
United States
United States
United States
United States
CRANE, LAWRENCE E
2014-03-24142234804-AMINO-4-OXOBUTANOYL PEPTIDE CYCLIC ANALOGUES, INHIBITORS OF VIRAL REPLICATIONACHILLION PHARMACEUTICALS, INC.Abandoned -- Failure to Pay Issue FeeUS20140206604A1
Avinash Phadke
Xiangzhu Wang
Godwin Pais
Akihiro Hashimoto
Venkat Gadhachanda
Dawei Chen
Atul Agarwal
Suoming Zhang
Cuixian Liu
Shouming Li
Milind Deshpande
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
United States
BEANE, RANDALL L
2014-03-1314208195SOVAPREVIR TABLETSAchillion Pharmaceuticals Inc.Abandoned -- Failure to Respond to an Office ActionUS20140271855A1
Jennifer Hsing-Chung Chu
Gautam Shah
Avinash Phadke
United States
United States
United States
AHMED, HASAN SYED